Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Wilhelm

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Cancer Medicine|October 14, 2016
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical modelsDieter Zopf, Iduna Fichtner, Ajay Bhargava, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsYong S Chang, Jalila Adnane, Pamela A Trail, et al.
JAMA Surgery|August 17, 2022
American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive SummaryLinwah Yip, Quan-Yang Duh, Heather Wachtel, et al.
Journal of Translational Medicine|April 19, 2015
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibAndrea Li Ann Wong, Joline Si Jing Lim, Arvind Sinha, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancerPhilip Wickens, Harold Kluender, Julie Dixon, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Cancer Medicine|October 14, 2016
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical modelsDieter Zopf, Iduna Fichtner, Ajay Bhargava, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsYong S Chang, Jalila Adnane, Pamela A Trail, et al.
JAMA Surgery|August 17, 2022
American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive SummaryLinwah Yip, Quan-Yang Duh, Heather Wachtel, et al.
Journal of Translational Medicine|April 19, 2015
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenibAndrea Li Ann Wong, Joline Si Jing Lim, Arvind Sinha, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancerPhilip Wickens, Harold Kluender, Julie Dixon, et al.
Pageof 2